Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert

Patient Access Initiative Addresses €1 Billion Annual Market in Germany BERKELEY, US – MAINZ, Germany – January 18, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of a corporate health program in Germany for ColoAlert, its highly […]

Mainz Biomed Provides Year-End 2022 Corporate Review

BERKELEY, US – MAINZ, Germany – January 3, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a corporate summary for the fiscal year ended December 31, 2022. Key Commercial, Operational and Product Development Highlights Launched U.S.-based eAArly DETECT […]

Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

ReconAAsense study examining the clinical performance of mRNA and DNA test combined with a fecal immunochemical test for early detection of advanced adenoma and colorectal cancer to enroll 15,000 subjects across the United States, results expected in 2025 Aims to enhance technical profile of the Mainz Biomed test to identify advanced adenomas (AA), a type […]

Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

BERKELEY, US – MAINZ, Germany – November 22, 2022 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable conferences in November and December 2022, Deutsches Eigenkapitalforum 2022 and Cantor Fitzgerald’s […]

Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert

eAArly DETECT expected to complete enrollment in Q1 2023 with results in 1H 2023 Enhances ColoFuture’s demographic profile and expedites data read-out timeline Potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC)   BERKELEY, US – MAINZ, Germany – November 15, 2022 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” […]

Mainz Biomed Provides Third Quarter 2022 Update

BERKELEY, US – MAINZ, Germany – November 2, 2022 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer today provided an update on accomplishments during the third quarter which ended September 30, 2022. Key Highlights and Recent Developments Expanded European and international commercial […]

Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts

Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and Financial Strategy Company to Hold Extraordinary General Meeting Week of December 12, 2022 BERKELEY, US – MAINZ, Germany – September 28, 2022 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics […]

Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board

Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana University Hospital in Indianapolis BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing […]